DE60326264D1 - Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält - Google Patents

Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält

Info

Publication number
DE60326264D1
DE60326264D1 DE60326264T DE60326264T DE60326264D1 DE 60326264 D1 DE60326264 D1 DE 60326264D1 DE 60326264 T DE60326264 T DE 60326264T DE 60326264 T DE60326264 T DE 60326264T DE 60326264 D1 DE60326264 D1 DE 60326264D1
Authority
DE
Germany
Prior art keywords
aminosaute
segment
materials
inflammation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60326264T
Other languages
German (de)
English (en)
Inventor
Lars T Hellman
Rikard Holmdahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resistentia Pharmaceuticals AB
Original Assignee
Resistentia Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals AB filed Critical Resistentia Pharmaceuticals AB
Application granted granted Critical
Publication of DE60326264D1 publication Critical patent/DE60326264D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
DE60326264T 2002-12-02 2003-12-01 Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält Expired - Lifetime DE60326264D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43027802P 2002-12-02 2002-12-02
PCT/IB2003/006344 WO2004050111A2 (fr) 2002-12-02 2003-12-01 Techniques et materiaux de traitement d'etats inflammatoires

Publications (1)

Publication Number Publication Date
DE60326264D1 true DE60326264D1 (de) 2009-04-02

Family

ID=32469435

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60326264T Expired - Lifetime DE60326264D1 (de) 2002-12-02 2003-12-01 Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält

Country Status (15)

Country Link
US (2) US7361742B2 (fr)
EP (1) EP1569958B1 (fr)
JP (1) JP2006507834A (fr)
KR (1) KR20050090390A (fr)
CN (1) CN1745098A (fr)
AT (1) ATE423133T1 (fr)
AU (1) AU2003288472A1 (fr)
CA (1) CA2508302A1 (fr)
DE (1) DE60326264D1 (fr)
ES (1) ES2323692T3 (fr)
MX (1) MXPA05005909A (fr)
NO (1) NO20052714L (fr)
NZ (1) NZ540735A (fr)
RU (1) RU2344144C2 (fr)
WO (1) WO2004050111A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462325B2 (en) * 2001-11-30 2008-12-09 Nomadics, Inc. Luminescent polymer particles
JP2006507834A (ja) * 2002-12-02 2006-03-09 レジステンティア ファーマシューティカルズ アーベー 自己ｃ５アミノ酸セグメントおよび非自己アミノ酸セグメントを含むポリペプチドを用いて炎症状態を治療するための方法及び材料
CN103143004A (zh) * 2005-02-04 2013-06-12 萨瓦克公司 存活蛋白肽疫苗
US7858363B2 (en) * 2006-07-22 2010-12-28 Zymo Research Corporation Plasmid DNA isolation
KR100973428B1 (ko) 2008-05-19 2010-08-03 한국과학기술연구원 말토오스 결합 단백질을 이용한 생리활성 폴리펩타이드의고정화 방법
EP2468295A1 (fr) 2010-12-21 2012-06-27 Affiris AG Vaccins à base de peptides de la proteine C5a du complement
TR201903840T4 (tr) 2012-02-20 2019-04-22 Swedish Orphan Biovitrum Ab Publ İnsan tamamlayıcı C5'e bağlanan polipeptitler.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NO162210C (no) 1987-07-20 1989-11-22 Fasting Biotech As Monoklonale antistoffer mot c5a for in-vitro anvendelse ved immunologiske kvantitative teknikker eller ved isolering av c5a.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1996039503A1 (fr) 1995-06-05 1996-12-12 Novartis Ag ANTAGONISTES DES RECEPTEURS DE C5a NE PRESENTANT SENSIBLEMENT AUCUNE ACTIVITE AGONISTE ET LEURS PROCEDES DE PREPARATION
EP0859625B1 (fr) * 1995-10-20 2008-06-25 University Of Nebraska Board Of Regents Composition et procedes permettant d'accentuer les reponses immunitaires dues aux cellules presentatrices d'antigene
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
JP2006507834A (ja) * 2002-12-02 2006-03-09 レジステンティア ファーマシューティカルズ アーベー 自己ｃ５アミノ酸セグメントおよび非自己アミノ酸セグメントを含むポリペプチドを用いて炎症状態を治療するための方法及び材料

Also Published As

Publication number Publication date
US20040214768A1 (en) 2004-10-28
KR20050090390A (ko) 2005-09-13
MXPA05005909A (es) 2005-08-26
NO20052714D0 (no) 2005-06-06
NO20052714L (no) 2005-08-10
WO2004050111A3 (fr) 2004-07-29
NZ540735A (en) 2008-08-29
CA2508302A1 (fr) 2004-06-17
EP1569958A2 (fr) 2005-09-07
US7361742B2 (en) 2008-04-22
WO2004050111A2 (fr) 2004-06-17
ATE423133T1 (de) 2009-03-15
ES2323692T3 (es) 2009-07-23
US20080262197A1 (en) 2008-10-23
RU2005120785A (ru) 2006-01-20
RU2344144C2 (ru) 2009-01-20
CN1745098A (zh) 2006-03-08
EP1569958B1 (fr) 2009-02-18
JP2006507834A (ja) 2006-03-09
AU2003288472A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
RU2467016C2 (ru) Антитела к il-22 человека и их применение
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
EP1603949B8 (fr) Anticorps diriges contre le recepteur humain de l'il-21 et utilisations correspondantes
MX2019007500A (es) Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp.
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
WO2006116181A3 (fr) Proteines regulatrices mediatrices des lymphocytes t et leurs utilisations
BR112012008665A2 (pt) tratamento de câncer
ATE473294T1 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
ATE523523T1 (de) Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
NO20052714D0 (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
DE602005013947D1 (de) Antikörper gegen hundepankreaslipase
ATE462727T1 (de) An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese
DE60315815D1 (de) ANTAGONISTISCHE HUMANE ANTI-hFAS-LIGAND-ANTIKÖRPER UND FRAGMENTE DAVON
DE602005022757D1 (de) Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
DE602005025459D1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition